Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21955580 | 0.99 | PKM (0.41) | PKMPKLRSCN9ASCN5AHTR6 | |
| SCHEMBL20727281 | 0.88 | HTR6 (0.49) | PKMPKLRHTR6 | |
| Hydrochloric Acid SCHEMBL21955534 | 0.87 | HTR6 (0.48) | PKMHTR6 | |
| SCHEMBL20727287 | 0.86 | HTR6 (0.39) | PKMSCN9ASCN5AHTR6 | |
| Hydrochloric Acid SCHEMBL21955571 | 0.85 | HTR6 (0.39) | PKMSCN9ASCN5AHTR6 | |
| Hypochlorous Acid SCHEMBL23035191 | 0.85 | HTR6 (0.47) | PKMHTR6 | |
| SCHEMBL20727275 | 0.83 | HTR6 (0.51) | PKMPKLRHTR6 | |
| Hydrochloric Acid SCHEMBL21955559 | 0.83 | HTR6 (0.52) | PKMPKLRHTR6 | |
| Hypochlorous Acid SCHEMBL23035161 | 0.81 | HTR6 (0.48) | PKMPKLRHTR6 | |
| SCHEMBL20727270 | 0.80 | HTR6 (0.47) | PKMPKLRHTR6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | claimed |
| EP-3649124-B1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2021-03-03 | — | — | EP | claimed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | claimed |
| EP-3649124-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | Suven Life Sciences Limited (IN) | 2020-05-13 | — | — | EP | claimed |
| WO-2019030641-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-02-14 | — | — | WO | claimed |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | disclosed |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | disclosed |
| EP-3649124-B1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3649124-B1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | disclosed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | disclosed |
| EP-3649124-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | Suven Life Sciences Limited (IN) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019030641-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019030641-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1B | PKM 2294/4885PKLR 3130/4885SCN9A 972/4885 |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | HTR6, HTR5A, HTR1B | PKM 2294/4885PKLR 3130/4885SCN9A 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.